Indian women in US also go for sex selection to have sons
By Times of India,
The Times of India
| 06. 08. 2011
Under cultural pressure to have sons, some Indian immigrant women are using reproductive technologies and liberal abortion policies in the US to abort female foetuses, according to a study conducted by University of California.
The women used sperm sorting or in-vitro fertilisation and implanted only the male embryos. Others aborted female foetuses.
The study doesn't mention how widespread the practise is, it covers a small sample group. Researchers interviewed 65 immigrant Indian women in California, New Jersey and New York who pursued foetal sex selection between September 2004 and December 2009.
Of the women, 40 percent had terminated prior pregnancies when carrying a female; 89 percent who found out they were carrying a girl during the interview period, had an abortion.
The women came from various religious and educational backgrounds and approximately half the women interviewed held jobs outside the home.
These results were consistent among all education levels; thirty eight had finished high school, 12 had graduated from college and 15 held advanced degrees in medicine, law, business, nursing and scientific research.
In addition, women who carried a female...
Related Articles
By Timnit Gebru and Émile P. Torres, First Monday | 04.14.2024
The stated goal of many organizations in the field of artificial intelligence (AI) is to develop artificial general intelligence (AGI), an imagined system with more intelligence than anything we have ever seen. Without seriously questioning whether such a system can...
By Harold Brubaker, The Philadelphia Inquirer | 04.04.2024
Acompany started by University of Pennsylvania scientist Jim Wilson has received FDA approval to test a form of gene editing in infants for the first time in the United States, the company said Thursday.
The Plymouth Meeting company, iECURE, is...
By Jason Kehe, Wired | 04.11.2024
God help the babies! Or, absent God, a fertility startup called Orchid. It offers prospective parents a fantastical choice: Have a regular baby or have an Orchid baby. A regular baby might grow up and get cancer. Or be born...
By Nick Paul Taylor, BioSpace | 03.14.2024
A U.K. watchdog balked at the cost-effectiveness of Vertex Pharmaceuticals’ CRISPR-based sickle cell disease therapy Thursday, recommending against funding the treatment unless uncertainties can be cleared up satisfactorily.
The U.K. became the first country to authorize Vertex’s Casgevy (exagamglogene...